<DOC>
	<DOC>NCT02825420</DOC>
	<brief_summary>Non-interventional, multicenter, prospective, European study to describe the effectiveness of trabectedin + PLD in the treatment of relapsed ovarian cancer (ROC) patients according to SmPC regardless of previous use of an antiangiogenic drug</brief_summary>
	<brief_title>Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>Women aged 18 years or older. Presence of platinumsensitive relapsed ovarian cancer. Treatment and treated indication according to local label SmPC and reimbursement for trabectedin and PLD treatment. Prior treatment with a minimum of 1 cycle of trabectedin + PLD according to SmPC before inclusion in the study, and no more than 3 previous treatment lines. Written informed consent indicating that patients understand the purpose and procedures and are willing to participate in the study.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>